Avicena Announces Positive Phase II Data For A Combination Trial Involving AL-08 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)

Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, today announced positive Phase II data for a combination trial involving AL-08, the Company’s second generation proprietary drug candidate for the treatment of ALS. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 6th, 2007